Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Diagn Pathol. 2020 Sep 14;15(1):110. doi: 10.1186/s13000-020-01025-8.
Uterine tumors resembling ovarian sex-cord tumors (UTROSCTs) are rare mesenchymal neoplasms predominantly arising in perimenopausal and postmenopausal women. UTROSCTs with growth regulation by estrogen in breast cancer 1 (GREB1)-rearrangement or GREB1-rearranged uterine tumors are exceptionally rare, with only 12 previously reported cases. Here, we report a case of UTROSCT with the GREB1-nuclear receptor coactivator 2 (NCOA2) fusion gene.
A 57-year-old woman presented with a 10.0 cm uterine mass. The tumor was composed of short spindle or epithelioid cells, arranged in diffused sheets, nested, and trabecular/cordlike. The tumor harbored the GREB1-NCOA2 fusion gene, as confirmed by RNA sequencing. The tumor recurred in the pelvis at 30 months after the initial diagnosis. We also compared the clinical and pathologic features of this case with those of the 12 previously published uterine GREB1-rearranged tumors. Of the combined 13 cases (present case and 12 previous cases), the mean age of patients was 64.8 years (range, 51-74 years). Of the nine reported cases of GREB1-rearranged tumor with follow up, four cases recurred or metastasized (44.4%). Microscopically, most tumors (10/12, 83.3%) showed infiltrative growth, and two were well demarcated. Mitotic figures ranged from 0 to 14 per 10 high-power fields (2 mm; mean: 3.6). Lymphovascular invasion and necrosis were each present in two cases (2/12, 16.7% and 2/7, 28.6%, respectively).
This case provided further evidence that UTROSCTs with GREB1-rearrangement may have a high risk of recurrence/metastasis. Further studies are necessary to clarify the clinical features of this type of tumor, particularly the prognosis, potential treatment, and range of possible molecular events.
类似于卵巢性索肿瘤的子宫肿瘤(UTROSCT)是一种罕见的间叶性肿瘤,主要发生在围绝经期和绝经后妇女中。具有雌激素通过乳腺癌 1(GREB1)重排调节生长(GREB1-rearrangement)或 GREB1 重排的子宫肿瘤极为罕见,仅有 12 例先前报道的病例。在这里,我们报告了一例具有 GREB1-核受体共激活因子 2(NCOA2)融合基因的 UTROSCT。
一名 57 岁女性因 10.0cm 的子宫肿块就诊。肿瘤由短梭形或上皮样细胞组成,呈弥漫性片状、巢状和小梁/条索状排列。通过 RNA 测序证实肿瘤携带 GREB1-NCOA2 融合基因。在初次诊断后 30 个月,肿瘤在盆腔复发。我们还比较了该病例与 12 例先前报道的子宫 GREB1 重排肿瘤的临床和病理特征。在 13 例合并病例(本病例和 12 例先前病例)中,患者的平均年龄为 64.8 岁(范围,51-74 岁)。在 9 例有随访的 GREB1 重排肿瘤中,有 4 例复发或转移(44.4%)。显微镜下,大多数肿瘤(10/12,83.3%)呈浸润性生长,2 例边界清楚。每 10 高倍视野(2mm;平均值:3.6)的有丝分裂象数为 0-14 个。有 2 例(2/12,16.7%和 2/7,28.6%)分别出现淋巴血管侵犯和坏死。
本病例进一步证明,具有 GREB1 重排的 UTROSCT 可能有较高的复发/转移风险。需要进一步研究以阐明此类肿瘤的临床特征,特别是预后、潜在治疗方法和可能的分子事件范围。